Abstract: Tuberculosis (TB) remains the top killer from an infectious globally causing an estimated 1.674.000 million deaths worldwide. In 2016, WHO estimates 600.000 cases of rifampicin-resistant TB of which 490.000 had multidrug-resistant (MDR) and less than half of them survive after receiving currently recommended WHO treatment regimens, illustrating weaknesses in current treatment approaches. We review progress and advances in the development of new and repurposed TB drugs, treatment trials and host-directed therapies. Updates are provided on phase 3 trials of the new compounds bedaquiline, delamanid, pretomanid; phase 2 trials of sutezolid, SQ-109, LCB01-0371, PBTZ-169; and five new drugs in phase 1 development. Approved or repurposed drugs undergoing further testing are rifampicin, rifapentine, clofazimine, and linezolid. Update on ongoing clinical trials, which aim to shorten TB treatment and improve treatment outcome is given. Several new or repurposed antimicrobial drugs are in advanced trial stages for MDR-TB, and five antimicrobial drug candidates are in phase 1 (Q203, TBI-166, OPC-167832, GSK 070, TBA-7371) and 5 in pre-clinical studies. Specific issues of safety and toxicity; drug-drug interactions; Therapeutic Drug Monitoring are reviewed. A wide range of candidate host-directed therapies (HDTs) and immune-based treatments are being investigated to accelerate the eradication of M.tb infection and for use as adjunctive therapy in shortening duration of treatment, preventing permanent lung injury and improving treatment outcomes of MDR-TB. Ongoing clinical trials of HDTs for TB treatment, the current HDT development pipeline and translational research efforts for advancing further HDT options are presented. Ongoing clinical trials of HDTs for TB treatment, the current HDT development pipeline and translational research efforts for advancing further HDT options are presented.
INTRODUCTION
In 2016, there were an estimated 1.67 million deaths due to tuberculosis (TB), making the disease the infectious disease killer worldwide. 1 The 2017 World Health Organization (WHO) Annual TB Report estimates 490.000 cases of multidrug-resistant (MDR-TB) of whom less than half survive after receiving currently recommended WHO treatment regimens, [1] [2] [3] [4] [5] [6] revealing the dire need for new therapies and approaches for improving TB treatment outcomes. Many challenges remain in developing optimal TB treatment regimens. 7 Recently, concerted efforts between many stakeholders have worked towards developing short course, better tolerated and effective treatment regimens. Several new or repurposed antimicrobial drugs are in advanced trial stages for MDR-TB, and nine antimicrobial drug candidates are in phase 1 and 2 trials. A range of candidate host-directed therapies and immune-based treatments are also being developed to accelerate the eradication of Mycobacterium tuberculosis (Mtb) infection, shorten the duration of treatment, prevent permanent lung injury and prevent new drug resistance.
In this article, we review advances and progress in the new and repurposed TB drugdevelopment pipeline, host-directed therapies. We provide an update of ongoing clinical trials, aimed at shortening TB treatment, improving treatment outcomes in MDR-TB, and preventing TB in people with latent TB infection (LTBI). Results of trials assessing the efficacy of three new anti-TB drugs, bedaquiline, delamanid, and pretomanid are reviewed.
Specific issues of safety and toxicity; drug-drug interactions; Therapeutic Drug Monitoring (TDM) and use people living with HIV, those with TB meningitis, pregnant women, and children are discussed.
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PROGRESS IN NEW TB DRUG DEVELOPMENT AND EVALUATION
Development of new and repurposed drugs and treatment regimens for TB has entered a promising phase. [15] [16] [17] [18] The status of the pipeline for new anti-TB drugs up to November 1st 2017 is shown in Figure 1 . The class of drugs, mechanisms of action and trial evaluation phase with relevant sponsor is shown on Table 1 . PBTZ-169 will enter phase 2 EBA (Early Bactericidal Activity), new compound (Q203) completing a Phase I trial in 2017 and TBA-7371 entering phase 1. However, with these advances there have also been some setbacks:
sutezolid (undergoing phase 2 trials) has to re-perform some phase 1 studies; the development of AZD5847 was officially ended (due to lack of demonstrated anti-TB activity); the development of TBA-354 was discontinued (due to signs of neurotoxicity in the Phase I trial), 19 and SQ109 has not demonstrated anti-mycobacterial activity, (however it may still retain usefulness as a companion drug and therefore function to protect the action of core drugs by raising the resistance threshold). 20 There are twelve anti-TB drugs in clinical development for the treatment of drug-susceptible, MDR-TB or latent TB infection (LTBI), of which nine are new, and three are already approved or repurposed. Table 2 provides a comprehensive list of the planned, ongoing and recently completed clinical trials on drugsusceptible and drug-resistant TB as of November 1st, 2017.
Drug-susceptible TB
The WHO recommends treatment for drug-susceptible TB with a two-month intensive phase with daily quadruple first-line TB drugs (isoniazid, rifampin, pyrazinamide, ethambutol),
followed by a 4-month continuation phase of isoniazid and rifampin. Shorter and simplified anti-TB regimens may increase patient adherence. Four-month standard regimens are, so far, only recommended in the American Thoracic Society guidelines for minimal disease, sputum smear, and culture negative cases. There are some ongoing studies to optimize the use of approved drugs and improving formulations, pill counts. 21 Of note new better tasting fixeddosed combination tablets are now available for paediatric use, which simplify dosing in children weighing less than 25kg, 22 while improving drug delivery and drug levels. 23, 24 A study by Amagon et al. suggests a reduction of liver toxicity of the standard quadruple regimen when associated with methionine and vitamin B complex. 25 Isoniazid, a cornerstone of anti-TB medications, is included in high doses in the shorter MDR-TB regimen. Isoniazid resistance can lead to worse outcomes and higher relapse rates; several studies have been performed to identify strategies to treat isoniazid-monoresistant TB more effectively. [26] [27] [28] The on-going ACTG5312 trial is testing whether increasing the dosage of isoniazid can help to overcome existing low-level resistance to the drug. High-dose isoniazid is also being used in the NEXT-TB trial. The RIFASHORT, and STAND trials are focused on shortening the current pan-sensitive TB regimen, evaluating the utility of rifapentine, high dose of A recent phase 2 study demonstrated that although 20mg/kg of rifampicin did not increase efficacy it did not lead to increased adverse events. 29 The PanACEA trial tested four experimental arms with rifampin dosages of 35 mg/kg, 20 mg/kg, and 10 mg/kg in various regimens against the standard of care for drug-susceptible (DS-TB). The only arm to show significantly faster time to culture conversion (TTCC) in liquid media was the DS-TB standard of care with the rifampin dose increased to 35 mg/kg. Arms containing SQ109 and moxifloxacin failed to show superiority to the standard of care. 30 Rifapentine, is being tested as a flat, not weight-based, dose of 1200 mg daily in a phase 3 study TBTC S31/ACTG A5349 as part of two four-month regimens for shortened treatment of DS-TB enrolling to date more than 1,400 of a target of 2,500 participants. 31 The first experimental regimen in this trial replaces rifampin with rifapentine and reduces the continuation phase to two months. The second experimental regimen is the same as the first, but replaces ethambutol with moxifloxacin and continues moxifloxacin for the continuation phase. The TRUNCATE-TB strategy phase 2c trial will test whether DS-TB treatment can be shortened to two months for some patients using combinations of new and repurposed drugs, including the rifamycins, utilising adaptive design. 32 Recently, the use of another rifamycin (rifabutin) was associated with improved treatment outcomes in rifabutin-susceptible cases. 33 The phase II Opti-Q study sets out to identify the optimal dose of levofloxacin, in patients with MDR-TB; results are expected in spring 2018. The study will evaluate levofloxacin doses of 11mg/kg, 14 mg/kg, 17 mg/kg, and 20 mg/kg, all taken daily for six months with an optimized background regimen. 34 Levofloxacin is also being used in the H-35265 trial, the NEXT trial, the STREAM trial, and in the MDR-END study. 35 Moxifloxacin is similarly being used in a number of ongoing trials and is being frequently utilized as a substitute for isoniazid or ethambutol in mono-resistant cases or patients with tolerability or contraindications. Resistance to the latest generation fluoroquinolones at the clinical breakpoint is still uncommon, a finding supporting current WHO recommendations to use moxifloxacin or gatifloxacin in the treatment of MDR-TB.
36
Drug-resistant tuberculosis
The updated classification of new anti-TB drugs by WHO is given in table 3, 37 The taxonomy of anti-TB drugs, and their combinations are undergoing a rapid transformation as a result of clinical trials and meta-analyses. 38 ,39 A 9-12-month standardised regimen is recommended by WHO for all patients with pulmonary MDR/rifampicin-resistant (RR)-TB (excluding pregnant women and extrapulmonary cases) not previously treated with second line agents and susceptible to fluoroquinolones and aminoglycosides. 37 This regimen consists of an intensive phase with gatifloxacin/moxifloxacin, kanamycin/amikacin, ethionamide/prothionamide, clofazimine, high dose or 10mg/kg isoniazid (max 600mg a day), ethambutol and pyrazinamide for 4-6 months, followed by a continuation phase of 5 months with gatifloxacin/moxifloxacin, clofazimine, ethambutol, and pyrazinamide. 40, 41 However, the appropriate management of such regimens is essential in order not to select for further resistance; adequate drug susceptibility testing should be provided for all cases, M/XDR-TB case management to highly experienced clinicians based on international guidelines is recommended. All these agents require a careful management in the context of individualised regimens under close clinical and laboratory monitoring. [42] [43] [44] The "Bangladesh'' shorter standardized regimen, achieved a relapse-free cure of 87.9%
among 206 patients, this regimen achieved < 1% failure and 90% relapse-free cure. 45 Moreover, an update of this study has shown that 84.4% of the 515 patients had a bacteriologically favourable outcome. 40 The only difference between the Bangladesh regimen and the WHO shorter regimen is the substitution of gatifloxacin for moxifloxacin. A metaanalysis reported that shorter regimens were effective in treating MDR-TB; however, failure/relapse was associated with fluoroquinolone resistance with an OR of 46. 
Updates on bedaquiline and delamanid
By September 2017, an estimated 10,164 patients had received bedaquiline, two-thirds of whom are in South Africa. 53 Concerns about the safety of bedaquiline were based on the ten Relapse free cure to date was 26/30 (87%). All patients were culture negative at four months-65% were already negative by eight weeks. 56 NIX-TB will roll over in November 2017, into the new ZeNIX trial -dose-ranging for LZD.
The bedaquiline phase III study, STREAM Stage II, is ongoing and results are expected in December 2021. 57 Other important trials including bedaquiline are NEXT-TB study TB-PRACTECAL and endTB. [58] [59] [60] The NEXT study is an open-label trial of a 6-9-month injection-free regimen containing bedaquiline, ethionamide or high-dose isoniazid, linezolid, levofloxacin, and pyrazinamide, compared with the WHO-recommended 12-month shorter regimen for MDR-TB treatment.
The TB-PRACTECAL trial is a Phase II/III adaptive trial to evaluate the safety and efficacy of 6-month regimens that contain bedaquiline, pretomanid and linezolid, with or without moxifloxacin or clofazimine, for the treatment of adults with MDR-TB or XDR-TB. The endTB is a Phase III trial that will compare several regimens for treatment of MDR-TB or XDR-TB with the current WHO standard of care. The regimens being tested contain bedaquiline or delamanid (or both), moxifloxacin or levofloxacin, and pyrazinamide plus linezolid or clofazimine (or both), in various combinations.
Initial findings from the ongoing NC-005 phase II trial which has seen its follow-up increased to month 24 was presented at the 2017 CROI suggest that a combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ) has both good bactericidal activity and safety. 61 The TB Alliance is planning to test this regimen in a more substantial phase III trial, NC-008 (ZeNIX). The AIDS Clinical Trials Group (ACTG) study A5343 in its three arms adds bedaquiline, delamanid, and a combination of the two to the WHO-recommended shortened MDR-TB regimen (with clofazimine removed in each case as a result of the increased risk of QT prolongation when used with bedaquiline). The study will provide important information about the safety and pharmacokinetics of using these two new drugs together.
In a recent systematic review of 1,293 published cases treated with bedaquiline, 53 details on QT≥450 msec was available for 35/329 cases (10%) and QT≥500 msec for 42/1,293 cases (3.2%). In 44/1,293 (3,4%) cases bedaquiline was discontinued due to adverse events, while only 8/857 (0.9%) discontinued the drug specifically for QT prolongation (2 of these 8 cases being able to re-start it after temporary interruption). There is growing data to support the efficacy and safety of delamanid in children above the age of 6, Otsuka Trial 233 is on-going with 6 month pharmacokinetic (PK)/safety in all paediatric weight groups with results in 2020, following Trial 232 with 18day PK/safety in same weight groups, results due out in 2018. 64, 69, 70 Delamanid is also being tested in a number of new trials, most notably endTB ( Table 2 ). The MDR-END trial (Seoul National University hospital), which is evaluating a regimen containing delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months. The same regimen as the MDR-END trial, with arms for various shorter durations, will be studied in the H-35265 trial.
Delamanid
Recently, there have been reports of treatment with delamanid and bedaquiline in combination; this was previously not recommended in the absence of evidence. However there is growing evidence that the combination may well be tolerated. 71, 72 There are two trials which are currently recruiting patients however results are not expected till 2020-1.
73,74
Whilst WHO does not recommend this combination, it recognises that physicians may require guidance and has provided recommendations including active safety drug monitoring which may provide for more rapid and robust phase 4 safety data collection.
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Pretomanid
Pretomanid is a nitroimidazole developed by the Global Alliance for TB Drug Development (TB Alliance). It is currently being tested as part of three potential combination regimens for the treatment of both drug-susceptible and drug-resistant TB. The phase III STAND trial, which tests a four-or six-month combination of pretomanid, moxifloxacin, and pyrazinamide for the treatment of both DS and drug-resistant (DR)-TB, was cleared to resume enrolment and is following up 284 enrolled participants. It is one of the three drugs in the NIX-TB regimen. It will also be included for further study in people with XDR-TB, pre-XDR-TB and patients with non-responsive or treatment-intolerant MDR-TB. Pretomanid will also feature together with bedaquiline-moxifloxacin and pyrazinamide as a regimen in the TB Alliance's planned NC-008 trial. NC-008 SimpliciTB is a phase III trial that tests a regimen including pretomanid and bedaquiline. Promising results support the use of this BPaMZ (Bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimen from the NC-005 trial, 77 Pretomanid is also being studied in multiple arms of phase II/III TB-PRACTECAL study.
Repurposed drugs
Clofazimine, an anti-leprosy drug, has demonstrated sterilising and treatment shortening potential. Its improved version TBI-166 has entered phase 1 trials and is hoped will not produce skin discolouration. 78 Encouraging evidence is also available for a large programmatic study in Brazil. 79 Carbapenems may have a future role in the treatment of tuberculosis. However, a lack of an active oral formulation and the necessity of combining amoxicillin-clavulanate (to protect it from ß-lactamases) renders these compounds less appealing, even though some appear very active with excellent tolerability and safety. 
UPDATES ON TB DRUGS FOR PREVENTIVE THERAPY
Clinicians and patients have long desired shorter, more tolerable, and safer alternatives for treatment of latent Mtb infection (LTBI) than standard daily isoniazid for 9 or more months. 2018 as an open label study. 88 TB-CHAMP will enrol 1,556 children age 5 and younger at sites in South Africa. 89 The ACTG and IMPAACT networks are partnering on the PHOENIX study (A5300B, 
Eicosanoid modulators
Eicosanoids are generated by cyclooxygenase (COX) and lipoxygenase (5-LOX) metabolism of arachidonic acid to generate prostaglandins and leukotriene, 100 respectively. Selective COX-2 inhibitors decrease unproductive inflammation and improve survival in murine TB by direct anti-mycobacterial activity. [101] [102] COX2-inhibition is however, also associated with cell necrosis, which favours Mtb survival. 103 Zileuton, a 5-LOX inhibitor, approved for use in asthma, increases PGE2 and inhibits leukotrienes to limit type I IFN-mediated lung pathology. It improves survival of Mtb-infected mice. 104 The eicosanoid pathway thus represents a complex target of TB HDT as the effect is likely dependent on infection stage, as PGE2 has protective effects early during infection but impairs anti-TB immunity during later stages.
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Cholesterol-lowering drugs
In addition to lipid-lowering properties, statins possess potent anti-inflammatory activities 106 with beneficial effects in TB. 107 As adjunctive therapy in murine TB, statins shorten the time to culture negativity by 1 month, reduce tissue pathology, decrease the proportion of culturepositive relapse cases and enhance bacterial killing. [108] [109] Statin usage by newly diagnosed type-2 diabetics did however, not prevent development of TB, 110 and further studies are required.
PDE inhibitors
Inhibitors of phosphodiesterase (PDE)-3, PDE4 and PDE5, such as cilostazol, roflumilast, sildenafil and tadalafil, increase levels of cyclic-adenosine-monophosphate or cyclic guanosine monophosphate. 111 PDE inhibitors accelerate lung sterilization, reduce lung inflammation and promote lung repair by potentiating isoniazid bactericidal activity, limiting
TNFα production and reducing macrophage activation. [112] [113] There is insufficient data on the clinical and immunological impact of PDE inhibitors and further research is required.
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Immune checkpoint inhibitors
The use of immune-oncological products such as anti-programmed cell death-1 (PD-1) and anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) have been clinically promising in the treatment of solid cancers. Immune regulatory checkpoints are perturbed in TB and linked to T-cell exhaustion. 115 Signalling via immune checkpoints inhibit T-and B-cell function 116 . Checkpoint inhibitors have been successfully employed in various cancers, specifically the monoclonal antibodies nivolumab and ipilimumab, against PD-1 and CTLA-4, respectively. 117 Inhibition of CTLA-4 enhances immune responses without improving bacillary clearance. Polymorphisms in CTLA-4 were linked to TB susceptibility. 118 Inhibition of the PD1/PD-L1 pathway enhances Mtb-specific responses in humans, 119 but not in mice. 120 Immune checkpoint inhibition treatment can result in development of active TB disease. This is likely due to excessive inflammation and increased focal necrosis. 121 Trials on the use of checkpoint inhibitors which block the PD1/PD-L1 pathway as adjunt to TB therapy are being considered.
Vitamins
Vitamin D3 (vitD3) moderately accelerates time to sputum conversion. 122 VitD3 deficiency is a risk factor for development of TB disease, 123 although a randomised control trial failed to show a profound effect on TB treatment outcome. 124 Further trials are required to accurately define the value of vitD3 as TB HDT. Vitamin A (vitA) possesses host immunomodulatory potential and in vitro anti-mycobacterial capabilities, 125 deficiency strongly predicts the risk of incident TB amongst TB household contacts (HHC) and supplementation (with zinc)
improves TB treatment outcomes. 126 The vitA derivative, all-trans-retinoic acid (ATRA), decreased Mtb burden by reducing cellular cholesterol and inducing phagosomal acidification. 127 These favourable outcomes could however not be repeated in other TB treatment studies.
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Kinase modulators
Targeting cancer drugs such tyrosine kinase inhibitors are being evaluated in preclinical models of TB, with considerable success. Several protein kinase inhibitors are available for clinical use. 129 Imatinib, a tyrosine kinase inhibitor, reduces bacterial load and lung pathology, likely by enhancing autophagy, phagosomal acidification and myeloid cell mobilization, [130] [131] and is currently being tested for its safety and immunogenicity as repurposed TB treatment. Adenosine monophosphate-activated protein kinase (AMPK) regulates cellular energy levels, T-cell differentiation and development of memory. 132 AMPK is activated by metformin, a type-2 diabetes drug, 133 that reduces bacterial burden and ameliorates lung pathology in mice and humans by enhancing autophagy and increasing ROS production. 92 Metformin adjunctive treatment however failed to improve sterilizing activity and TB relapsed in mice, with no significant effect being reported for culture conversion rates in diabetes mellitus patients with TB.
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Cellular therapy
Cellular therapy has shown promise in the cancer field, 135 and is being investigated for use as adjunct therapy for drug-resistant TB. 136 Mesenchymal stromal cells (MSC) are nonhematopoietic progenitor cells with immunomodulatory and antibacterial properties, [137] [138] that improve immune responses and lung pathology in human and murine TB. 
Micro-RNA
miRNA are small non-coding RNAs regulating gene expression and can affect host immunity to Mtb infection through modulation of inflammation, TNFα, IL6, chemokines and stimulation of macrophage polarization. [146] [147] There is emerging evidence that miRNAs could serve as cancer immunotherapy and could serve as therapeutic targets in TB.
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Cytokines and proteases TNF-α is essential to granuloma integrity, macrophage antimicrobial activity and ROSmediated Mtb killing. 150 TNF-α can however, also trigger cell necrosis and exacerbate inflammation, thereby aggravating TB pathology. 151 TNF-α blockers and anti-TNF-α monoclonal antibodies, such as thalidomide and infliximab, successfully control severe TB . 152 On the other hand, TNF-α inhibition destabilizes granulomas, reactivates Mtb bacilli and increases the risk of TB disease. 153 IFN-γ is important to protective anti-TB immunity and administration has nominal benefit in drug-sensitive, 154 and drug-resistant TB. Centre at UCL Hospitals and is in receipt of an NIHR Senior Investigatorship.
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